Brief: Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab

Oncternal Therapeutics

13/04/2022 13:40

April 13 (Reuters) - Oncternal Therapeutics Inc  ONCT.O :
    * ONCTERNAL THERAPEUTICS DEPRIORITIZES DEVELOPMENT OF
ONCT-216 TO
FOCUS RESOURCES ON PHASE 3 TRIAL FOR ZILOVERTAMAB IN THE
TREATMENT OF MANTLE CELL LYMPHOMA
    * ONCTERNAL THERAPEUTICS INC - DISCONTINUED ENROLLMENT OF
PHASE
1/2 TRIAL OF ONCT-216 IN EWING SARCOMA
    * ONCTERNAL - RESOURCES WILL BE PRIMARILY REALLOCATED TO
ZILOVERTAMAB GLOBAL REGISTRATIONAL PHASE 3 STUDY ZILO-301,
EXPECTED TO BE INITIATED IN Q3 2022
    * ONCTERNAL THERAPEUTICS INC - CASH RUNWAY TO FUND
OPERATIONS
GUIDANCE EXTENDED WELL INTO Q3 2023
    * ONCTERNAL THERAPEUTICS - EXPECTS TO INITIATE IND-ENABLING
GLP
TOXICOLOGY STUDIES AND GMP MANUFACTURING FOR ONCT-534 LATER THIS
QUARTER

Source text for Eikon:  ID:nGNX3fwnTw 
Further company coverage:  ONCT.O 

 ((Reuters.Briefs@thomsonreuters.com;))